Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268022
Max Phase: Preclinical
Molecular Formula: C40H67N11O19S2
Molecular Weight: 1070.17
Associated Items:
ID: ALA5268022
Max Phase: Preclinical
Molecular Formula: C40H67N11O19S2
Molecular Weight: 1070.17
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CS)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CS)C(=O)O
Standard InChI: InChI=1S/C40H67N11O19S2/c1-16(2)10-23(36(65)43-17(3)31(60)42-11-27(55)45-26(15-72)40(69)70)48-38(67)25(13-53)50-35(64)22(7-9-29(58)59)46-37(66)24(12-52)49-32(61)18(4)44-34(63)21(6-8-28(56)57)47-39(68)30(19(5)54)51-33(62)20(41)14-71/h16-26,30,52-54,71-72H,6-15,41H2,1-5H3,(H,42,60)(H,43,65)(H,44,63)(H,45,55)(H,46,66)(H,47,68)(H,48,67)(H,49,61)(H,50,64)(H,51,62)(H,56,57)(H,58,59)(H,69,70)/t17-,18-,19+,20-,21-,22-,23-,24-,25-,26-,30-/m0/s1
Standard InChI Key: ACORDUNGMGQPHE-IYXPPYDQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1070.17 | Molecular Weight (Monoisotopic): 1069.4056 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Cuffaro D, Ciccone L, Rossello A, Nuti E, Santamaria S.. (2022) Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition., 65 (20.0): [PMID:36250680] [10.1021/acs.jmedchem.2c01177] |
Source(1):